Practice question

Answer the question and get instant feedback.

Moderate1 month (B) or 3 months (C) is too short for standard‑risk ACS. Indefinite therapy (E) increases bleeding risk without clear benefit."Cardiology"moderate"

A 61-year-old with NSTEMI stabilized medically on aspirin and ticagrelor underwent PCI with DES. He asks how long to continue P2Y12 therapy. Bleeding risk is average. What is recommended?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.